Treatment-emergent adverse events for all study participants
| Up to week 16 | After week 16 | |||||
| Filgotinib 200 mg (n=5) | Lanraplenib 30 mg (n=4) | Filgotinib 200 mg (n=3) | Lanraplenib 30 mg (n=0) | Filgotinib 200 mg/lanraplenib 30 mg (n=1) | Lanraplenib 30 mg/filgotinib 200 mg (n=1) | |
| Subjects with any TEAE, n (%) | 3 (60.0) | 4 (100.00) | 1 (33.3) | – | 1 (100.0) | 1 (100.0) |
| Neutropenia | 2 (40.0) | 0 (0.0) | 0 (0.0) | – | 1 (100.0) | 0 (0.0) |
| Peripheral oedema | 0 (0.0) | 1 (25.0) | 1 (33.0) | – | 0 (0.0) | 0 (0.0) |
| Bronchitis | 0 (0.0) | 2 (50.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Furuncle | 1 (20.0) | 0 (0.0) | 0 (0.0) | – | 1 (100.0) | 0 (0.0) |
| Arthralgia | 0 (0.0) | 0 (0.0) | 1 (33.0) | – | 1 (100.0) | 0 (0.0) |
| Anaemia | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | 1 (100.0) | 0 (0.0) |
| Leucopenia | 1 (20.0) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Amaurosis fugax | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Vitreous floaters | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Dyspepsia | 1 (20.0) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Food poisoning | 0 (0.0) | 0 (0.0) | 1 (33.0) | – | 0 (0.0) | 0 (0.0) |
| Nausea | 1 (20.0) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Fatigue | 1 (20.0) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Pain | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | 1 (100.0) | 0 (0.0) |
| Nasopharyngitis | 0 (0.0) | 0 (0.0) | 1 (33.0) | – | 0 (0.0) | 0 (0.0) |
| Sinusitis | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| URI | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Contusion | 0 (0.0) | 0 (0.0) | 1 (33.0) | – | 0 (0.0) | 0 (0.0) |
| Fall | 0 (0.0) | 0 (0.0) | 1 (33.0) | – | 0 (0.0) | 0 (0.0) |
| Lymphocytes decreased | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Hyper-cholesterolaemia | 1 (20.0) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Hypo-albuminaemia | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Muscle spasms | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 1 (100.0) |
| MSK pain | 0 (0.0) | 0 (0.0) | 1 (33.0) | – | 0 (0.0) | 0 (0.0) |
| Lupus | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Headache | 1 (20.0) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Anxiety | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Acute kidney injury | 0 (0.0) | 1 (25.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Pollakiuria | 1 (20.0) | 0 (0.0) | 0 (0.0) | – | 0 (0.0) | 0 (0.0) |
| Rash | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | 1 (100.0) | 0 (0.0) |
Safety analysis set includes subjects who received at least one dose of study drug. Treatment-emergent events began on or after the study drug start date up to 30 days after permanent discontinuation of study drug or led to premature study drug discontinuation.
MSK, musculoskeletal; TEAE, treatment-emergent adverse event; URI, upper respiratory tract infection.